Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at the ASCO GU Cancer Symposium
23 févr. 2023 07h00 HE
|
Theralase Technologies Inc.
TORONTO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the ASCO GU Cancer Symposium
25 janv. 2023 07h00 HE
|
Theralase Technologies Inc.
TORONTO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase® Research - One of the Top 10 Most Downloaded Papers
24 juin 2022 07h00 HE
|
Theralase Technologies Inc.
TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase® Demonstrates Proof-of-Concept for Canadian-Made COVID-19 Vaccine
07 févr. 2022 07h00 HE
|
Theralase Technologies Inc.
TORONTO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...